The QualityStocks Daily Friday, March 24th, 2023

Today's Top 3 Investment Newsletters

The Online Investor(SI) $1.7200 +52.21%

QualityStocks(VIRI) $0.4450 +43.55%

MarketClub Analysis(NAAS) $5.8000 +38.76%

The QualityStocks Daily Stock List

Virios Therapeutics (VIRI)

RedChip, QualityStocks, TradersPro, Red Chip, PCG Advisory, MarketClub Analysis and MarketBeat reported earlier on Virios Therapeutics (VIRI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Virios Therapeutics Inc. (NASDAQ: VIRI) is a development stage biotechnology firm that is engaged in the development and commercialization of antiviral treatments for ailments linked to viral triggered abnormal immune responses.

The firm has its headquarters in Alpharetta, Georgia and was incorporated in 2012, on February 28th by William L. Pridgen. Prior to its name change in December 2020, the firm was known as Virious Therapeutics LLC. It operates in the health care sector, under the biotech and pharma sub-industry and serves consumers in the U.S.

The company’s objective is to enhance patient outcomes by finding the underlying cause of fibromyalgia as well as other conditions. Scientists propose that the overactive immune responses associated with activation of HSV-1 (Herpes Simplex Virus-1) tissue may be a possible cause of chronic ailments like functional somatic syndrome, chronic fatigue syndrome, irritable bowel disease and fibromyalgia. All these diseases are characterized by a waning and waxing manifestation of illness.

The enterprise’s lead drug candidate is a fixed dose combination of celecoxib and famciclovir known as IMC-1, which has been indicated for the treatment of fibromyalgia. Its end goal is to decrease viral-mediated illness burdens. The candidate is currently undergoing a phase 2b clinical trial, which is expected to end by the first quarter of 2022.

The firm’s IMC-1 candidate was recently awarded fast track designation by the FDA. The candidate, which has shown promising results, may soon be introduced to the market, which will not only benefit the patients who suffer from fibromyalgia but also bring in more investors into the firm.

Virios Therapeutics (VIRI), closed Friday's trading session at $0.445, up 43.5484%, on 7,209,137 volume. The average volume for the last 3 months is 27.528M and the stock's 52-week low/high is $0.218951/$9.1109.

Heliogen Inc. (HLGN)

QualityStocks, MarketBeat and FreeRealTime reported earlier on Heliogen Inc. (HLGN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Heliogen Inc. (NYSE: HLGN) is a renewable energy technology firm that is focused on the development of an AI-enabled, concentrated solar power plant which will use the power of sunlight to replace the use of fossil fuels.

The firm has its headquarters in Pasadena, California and was incorporated in 2013 by Bill T. Gross. Prior to its name change, the firm was known as Athena Technology Acquisition Corp. The firm serves consumers around the world.

The company is developing a solar solution which uses its advanced computer vision software to align an array of mirrors which reflect sunlight to a target placed on a sunlight refinery tower. Its modular system, which is powered by artificial intelligence, has been designed to deliver low-cost renewable energy in the form of power, heat or hydrogen fuel.

The enterprise’s solutions include HelioHeat, which is focused on the production of carbon-free heat to be used in heavy industrial processes, which include the making of petrochemicals, steel and cement. It also develops HelioPower, which delivers solar thermal energy made from sunlight using supercritical carbon dioxide turbines, to power data centers, industrial facilities and mining operations. In addition to this, the enterprise provides clean fuels like green hydrogen under HelioFuel, which can be used as fuel in heavy equipment and transportation.

The company was recently awarded the right to lease land in the Brenda Solar Energy Zone. It plans to develop a green hydrogen facility on the site for commercial-scale production of green hydrogen, which will not only bring in additional revenue into the firm, but also attract more investments as well.

Heliogen Inc. (HLGN), closed Friday's trading session at $0.2749, up 30.9048%, on 5,612,342 volume. The average volume for the last 3 months is 1.023M and the stock's 52-week low/high is $0.1881/$6.00.

Nano Mobile Healthcare (VNTH)

QualityStocks, Actual Gains, Stockpalooza, Promotion Stock Secrets, Honest Abe, OTCPicks, BUYINS.NET, TheMicrocapNews, PennyStockRumors.net, OTCPennyPicks.com, OTCNewsAlerts.com, Joe Penny Stocks, MadPennyStocks, Liquid Tycoon, JumpingPennyStocks.com, MarketClub Analysis, HotPennyInvest.com, OTCReporter, HotOTCChina.com, Penny Stock Pick Alert, HotOTCBuzz.com, HotOTC, FreeRealTime, FOX Penny Stocks, DSR News, CityOdds, BullRally, HotOTCPicks.com, PennyStockVille, WePickPennyStocks, The Penny Stock Bull, Super Nova Stock Picks, Super Hot Penny Stocks, StockRich, StockMister, StockEgg, SmartPennyInvest.com, RisingPennyStocks, Penny Stock Hub, PennyTrader Publisher, OTCSHUB, PennyStocks24, PennyStockPromo, PennyStockProfessor, PennyPickAlerts, Penny Stock Pulse, Penny Stock Pick Report, Winning Penny Stock Picks, Penny Stock MoneyTrain, Penny PayDay and Pumps and Dumps reported earlier on Nano Mobile Healthcare (VNTH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Nano Mobile Healthcare Inc. (OTC: VNTH) is a mobile health technology firm that is focused on the development of point-of-care and personalized screening, using applications based on chemical sensing techniques.

The firm has its headquarters in Boston, Massachusetts and was incorporated in 2010, on April 21st. Prior to its name change in September 2015, the firm was known as Vantage Healthcare Inc. The firm serves consumers in the United States.

The company has focused its initial efforts on screening for the presence of illnesses or the use of drugs. It is party to a strategic partnership agreement with a translational research firm known as Theranostics Laboratory. The company operates as a subsidiary of Nanobeak LLC.

The enterprise’s products are the convergence of bio-informatics, wireless technology and nano-electronics. They are based on patented technology invented by NASA. It develops small, hand-held screening devices which analyze and detect common components known as Volatile Organic Compound Signatures, from an individual’s breath and offer an early indication of chronic illnesses like heart failure. The enterprise has identified 2 markets the device can be used in, i.e. detecting the presence of cannabis in a driver’s breath and detecting lung cancer. Its secondary device testing indications include contagious illnesses like strep throat and various forms of cancer.

The company recently ventured into a new market with the development of its NFTsByGamers.com platform, which will develop a marketplace for the exchange and creation of NFTs in the gaming community. This move expands the company’s reach and will positively influence investments into the company, as well as boost the company’s overall growth.

Nano Mobile Healthcare (VNTH), closed Friday's trading session at $0.0009, up 28.5714%, on 173,488,293 volume. The average volume for the last 3 months is 865,478 and the stock's 52-week low/high is $0.0003/$0.0027.

Sonim Technologies (SONM)

QualityStocks, MarketBeat, StockMarketWatch, The Stock Dork, StocksEarning, StockRockandRoll, PennyStockLocks, Penny Stock 101, The Online Investor, StockEarnings and InvestorPlace reported earlier on Sonim Technologies (SONM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sonim Technologies Inc. (NASDAQ: SONM) (FRA: 2W9) is engaged in the provision of ruggedized mobile accessories and phones for task workers.

The firm is based in Austin, Texas and was incorporated in 1999 on August 5th by Joakin Wiklund, Sudu Srinivasan, Jai Kumar, Anush Gopalan, Isaac Eteminan and Ram Chandran. Prior to its name change in December 2001, the firm was known as NaviSpin.com Inc.

The company provides solutions in 3 categories namely, cloud-based software and application services; industrial-grade accessories; and, ultra-rugged mobile devices. It sells accessories, barcode scanners and ruggedized phones through distribution channels in Europe, South America and North America and sells its accessories and mobile phones primarily to wireless carriers in Canada and the U.S. It serves defense, agriculture, transportation, utilities, oil and gas, security and construction industries across the globe.

Its products include a portable communications system dubbed the Rapid Deployment Kit; hands-free in-vehicle voice communication solution, multi-bay charging accessories and remote speaker microphones, which are all industrial grade accessories and the Sonim XP3, XP5s and XP8, which are all based on the android platform and can attach to private and public wireless networks. The enterprise also offers SmartScanner products like an android-based tablet called Sonim RS80 and an LTE device that’s android-based called Sonim RS60.

The company recently entered into a partnership with Business Mobility Partners, a distributor of T-Mobile for business services and products. This move will allow business consumers for T-Mobile to access Sonim’s ultra-rugged devices, which will help extend the firm’s consumer reach and is bound to bring in more investors.

Sonim Technologies (SONM), closed Friday's trading session at $0.68, up 27.1979%, on 477,304 volume. The average volume for the last 3 months is 2,471 and the stock's 52-week low/high is $0.40/$1.0301.

electroCore (ECOR)

MarketBeat, BUYINS.NET, StreetInsider, QualityStocks, TradersPro, StockMarketWatch, PoliticsAndMyPortfolio, PennyStockScholar, OTCtipReporter, Penny Pick Finders, Profitable Trader Authority, Trades Of The Day, StockOnion, MarketClub Analysis, TopPennyStockMovers, InvestorPlace, HotOTC, Channelchek, Buzz Stocks and PennyStockProphet reported earlier on electroCore (ECOR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

electroCore, Inc. (NASDAQ: ECOR) (FRA: 43E) is a medical device firm that is focused on developing and commercializing various nVNS (non-invasive vagus nerve stimulation) therapies for treating various conditions in rheumatology, neurology, respiratory and psychiatry.

The firm has its headquarters in New Jersey and was incorporated in September 2005 by Thomas J. Errico, Peter S. Staats, Steven M. Mendez and Joseph P. Errico. It operates under the healthcare sector, in the biotech and pharma sub-industry and serves consumers across the globe.

The company centers mainly on headaches like cluster and migraine, in anxiety, depression, gastric motility disorders and epilepsy. It sells its products to patients via health care professionals in Canada, Australia, Italy, Germany, the U.S. and the United Kingdom

The enterprise develops a bioelectronics medical therapy platform which modulates neurotransmitters and immune function via its effects on both the central and peripheral nervous systems. It is involved in the development of a prescription-only nVNS therapy dubbed gammaCore indicated for the treatment of acute pain linked to episodic cluster headaches and migraines in adults. It also produces a reloadable and rechargeable handheld delivery system known as gammaCore Sapphire, which is prescribed on a monthly basis, for multi-year use.

The firm recently entered into an agreement with Kromax International Corp, for the distribution of its gammaCore Sapphire product. This agreement will allow the product to reach consumers in China and Taiwan, which will help extend the firm’s consumer reach and boost the company’s growth.

electroCore (ECOR), closed Friday's trading session at $5.34, up 24.7664%, on 215,529 volume. The average volume for the last 3 months is 152,887 and the stock's 52-week low/high is $2.925/$10.5045.

Noodles & Company (NDLS)

The Street, InvestorPlace, All about trends, StreetInsider, MarketBeat, Zacks, Daily Trade Alert, Street Insider, The Motley Fool, Wealth Daily, TraderPower, Trades Of The Day, StockMarketWatch, Money Morning, Kiplinger Today, Trading Concepts, TopStockAnalysts, StreetAuthority Daily, SmallCapNetwork, Barchart, Marketbeat.com, Greenbackers, Energy and Capital, MarketClub Analysis, FreeRealTime, Market Authority, BUYINS.NET, Money and Markets, Profit Confidential, ProfitableTrading, QualityStocks, SmallCap Network, SmallCapVoice, Stocks That Move, The Online Investor, TheOptionSpecialist, Uncommon Wisdom, Wall Street Daily, Wealth Insider Alert and Schaeffer's reported earlier on Noodles & Company (NDLS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Noodles & Company (NASDAQ: NDLS) (FRA: NO3) is a restaurant concept firm that is focused on operating and developing fast-casual restaurants.

The firm has its headquarters in Broomfield, Colorado and was incorporated in 1995 by Aaron Kennedy. It operates as part of the restaurants industry, under the consumer cyclical sector. The firm serves consumers in the United States.

The company is focused on creating exceptional mealtime experiences, at great value. This is their passion. Its mission is to nourish and inspire every team member, guest and the community they serve. From its menu to its service to the way it does business, the company’s fresh, unexpected human perspective sets it apart.

The enterprise develops and operates fast-casual restaurants. Its menu includes a variety of cooked-to-order dishes, including noodles and pasta, salads, soups and appetizers. The enterprise provides over 20 globally inspired dishes together on a single menu that is served in its restaurants, taken to-go, or delivered to its customers. It only uses the finest, most wholesome ingredients. Every entrée is prepared fresh and made to order. Their abundant menu is filled with bright, lively and comfortable flavors sure to satisfy any craving and nearly every dietary lifestyle or preference. The enterprise operates approximately 448 restaurants in 29 states, which includes 372 company locations and 76 franchise locations. Its restaurants are located in Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky and Maryland.

The company recently expanded its menu offerings with the return of its Backyard BBQ Chicken Salad. This move will help meet consumer demand while also bringing in additional revenues into the company.

Noodles & Company (NDLS), closed Friday's trading session at $4.67, off by 5.6566%, on 304,182 volume. The average volume for the last 3 months is 7.115M and the stock's 52-week low/high is $4.25/$6.78.

Brandywine Realty Trust (BDN)

MarketBeat, MarketClub Analysis, Marketbeat.com, StreetInsider, Schaeffer's, INO.com Market Report, Daily Trade Alert, The Online Investor, BUYINS.NET, InvestorPlace, Investors Alley, Kiplinger Today, QualityStocks, Trades Of The Day, The Street, Trading Concepts, SmarTrend Newsletters, Street Insider and Louis Navellier reported earlier on Brandywine Realty Trust (BDN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Brandywine Realty Trust (NYSE: BDN) (FRA: B2X) is a self-administered, self-managed, and fully integrated real estate investment trust that is engaged in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential, and mixed-use properties.

The firm has its headquarters in Philadelphia and was incorporated in 1986 by Gerard H. Sweeney. It operates as part of the REIT-Office industry, under the real estate sector. The firm serves consumers in the United States.

The company’s goal is to develop, build and manage the nation's most remarkable Class-A office and mixed use properties. Its purpose is to shape, connect and inspire the world around it through its expertise, the relationships it fosters, the communities in which people live and work, and the history they build together with their clients.

The enterprise operates through the following business segments: Philadelphia Central Business District, Pennsylvania Suburbs, Austin, Texas, Metropolitan Washington, D.C., and Other. The Philadelphia Central Business District segment includes properties located in the city of Philadelphia, Pennsylvania. The Pennsylvania Suburbs segment consists of properties in Chester, Delaware, and Montgomery counties. The Austin, Texas segment focuses on properties in the City of Austin, Texas. The Metropolitan Washington D.C. segment focuses on properties in the District of Columbia, Northern Virginia, and Southern Maryland. The Other segment offers properties located in Camden County, New Jersey and in New Castle County, Delaware.

The fund remains focused on generating value for its shareholders which will greatly influence overall growth.

Brandywine Realty Trust (BDN), closed Friday's trading session at $4.26, up 3.1477%, on 5,355,734 volume. The average volume for the last 3 months is 251,089 and the stock's 52-week low/high is $3.97/$14.55.

Nexters (GDEV)

StockEarnings, StocksEarning and QualityStocks reported earlier on Nexters (GDEV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Nexters Inc. (NASDAQ: GDEV) (FRA: 9T8) is a global game development firm that is focused on offering core gaming experiences to casual players on desktop and mobile.

The firm has its headquarters in Limassol, Cyprus and was incorporated in 2010 by Boris Gertsovsky and Andrey Fadeev. It operates as part of the electronic gaming and multimedia industry, under the communication services sector. The firm serves consumers around the globe.

The company strives to introduce the joy of core gaming experiences to casual players. It follows its own path of enriching casual gaming and providing opportunities to everyone who shares their goals and values. The company is one of the top five independent mobile game companies in Europe.

The enterprise has developed various games, including Hero Wars, Chibi Island, Throne Rush, Island Experiment and Island Questaway. Its Hero Wars game is available on both mobile and Web platforms. Its Hero Wars game includes defeating hydras with guild on mobile and complete the co-op adventures with the help of pets on the Web. The company’s Throne Rush game is a strategy game, which allows players to rule their own kingdoms and achieve prosperity while destroying enemies and capturing their wealth. The Chibi Island game helps to explore the secrets of the pyramid. Its Chibi Island game also includes thrilling mysteries, game modes and fun.

The company recently resumed trading on the NASDAQ, which will open it up to new growth and investment opportunities. This is in addition to creating value for its shareholders.

Nexters (GDEV), closed Friday's trading session at $3.88, up 12.4638%, on 5,578 volume. The average volume for the last 3 months is 159,363 and the stock's 52-week low/high is $6.38/$8.20.

Martin Midstream Partners (MMLP)

StreetInsider, TradersPro, MarketBeat, InvestorPlace, Marketbeat.com, QualityStocks, Daily Trade Alert, Zacks, Street Insider, InsiderTrades, Barchart, StockMarketWatch, StreetAuthority Daily, The Street, TheStreet Offers, Money Morning, Money and Markets, Top Pros' Top Picks, TopStockAnalysts, Leeb's Market Forecast, Trades Of The Day, Turn Key Oil, Uncommon Wisdom and SmarTrend Newsletters reported earlier on Martin Midstream Partners (MMLP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Martin Midstream Partners LP (NASDAQ: MMLP) is a company engaged in the provision of terminalling, processing, storage, and packaging services for petroleum products and by-products.

The firm has its headquarters in Kilgore, Texas and was incorporated in 2002. It operates as part of the oil and gas midstream industry, under the energy sector. The firm serves consumers in the United States.

The enterprise operates through the Terminalling and Storage, Transportation, Sulfur Services, and Natural Gas Liquids segments. Its Terminalling and Storage segment owns or operates 14 marine shore-based terminal facilities and 13 specialty terminal facilities that offer storage, refining, blending, packaging, and handling services for producers and suppliers of petroleum products and by-products. This segment also provides land rental services to oil and gas companies, as well as storage and handling services for lubricants and fuels. The Transportation segment operates a fleet of 700 trucks and 1,200 tank trailers; and 27 inland marine tank barges, 15 inland push boats, and an articulated offshore tug and barge unit to transport petroleum products and by-products, petrochemicals, and chemicals. The enterprise's Sulfur Services segment processes molten sulfur into prilled or pelletized sulfur, which is used in the production of fertilizers and industrial chemicals. Its Natural Gas Liquids segment stores, distributes, and transports natural gas liquids for wholesale deliveries to refineries, industrial natural gas liquid users, and propane retailers. Martin Midstream GP LLC serves as a general partner of the enterprise.

The company recently announced its latest financial results, with its CEO noting that they remained focused on strengthening its balance sheet and lowering its risk profile.

Martin Midstream Partners (MMLP), closed Friday's trading session at $2.6, up 1.5625%, on 16,343 volume. The average volume for the last 3 months is 549,463 and the stock's 52-week low/high is $2.39/$5.98.

Uniti Group (UNIT)

Schaeffer's, MarketClub Analysis, MarketBeat, Investors Alley, Kiplinger Today, StreetInsider, The Online Investor, Daily Trade Alert, The Street Report, The Wealth Report, Top Pros' Top Picks, InvestorPlace, Trades Of The Day, FreeRealTime, BUYINS.NET, Zacks, InsiderTrades, QualityStocks, The Street and Marketbeat.com reported earlier on Uniti Group (UNIT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Uniti Group Inc. (NASDAQ: UNIT) (LON: 0LJB) (FRA: 8XC) is an internally managed real estate investment trust that is focused on acquiring and constructing mission critical communications infrastructure.

The firm has its headquarters in Little Rock, Arizona and was incorporated in February 2014. It operates as part of the REIT-specialty industry, under the real estate sector. The firm serves consumers in the United States and Latin America.

The company operates through the Leasing, Fiber Infrastructure, Towers, Consumer CLEC, and Corporate business segments. The Leasing segment represents the real estate investment trust operations of the company and includes the results from leasing business; Uniti leasing, which engages in the acquisition of mission-critical communications assets and leasing them to anchor customers on either exclusive or shared-tenant basis. The Fiber Infrastructure segment refers to the operations of the fiber business of the company; Uniti Fiber, which offers infrastructure solutions, including cell site backhaul and dark fiber, to the telecommunications industry. On the other hand, the Towers segment encompasses Uniti Towers, which acquires and constructs tower-related real estate in the United States and Latin America. The Consumer CLEC segment is the operations of Talk America, which provides local telephone, high-speed internet and long distance services to customers in the eastern and central United States. The Corporate segment comprises of corporate and back office functions of the company.

The enterprise recently announced its latest financial results, with its CEO noting that they expected demand for its product offerings to remain robust as the need for higher bandwidth and dense fiber networks continues to grow. This will positively influence revenues into the firm while also bolstering its overall growth.

Uniti Group (UNIT), closed Friday's trading session at $3.37, up 1.506%, on 3,513,019 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.15/$14.17.

HIVE Blockchain Technologies Ltd. (HIVE)

QualityStocks, InvestorPlace, MarketClub Analysis, MarketBeat, StreetInsider, Early Bird, Marketbeat.com, StockMarketWatch, Greenbackers, Hit and Run Candle Sticks, Barchart, Stock Market Watch, WealthMakers, StockOodles, StreetAuthority Daily, The Night Owl, The Online Investor, TopStockAnalysts, Wall Street Resources and smartOTC reported earlier on HIVE Blockchain Technologies Ltd. (HIVE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The collapse of Sam Bankman-Fried’s FTX last year continues to cause reverberations, with the most recent being the filing of a class-action lawsuit against YouTube influencers who were vocal in promoting FTX to their followers. The plaintiffs want the court to award them damages worth $1 billion dollars.

Edwin Garrison is the leader of the plaintiffs, who filed their suit in Miami Division in Southern Florida on March 15, 2023. The suit alleges that the influencers actively promoted the cryptocurrency fraud executed by FTX, and that those influencers didn’t disclose that they were being compensated for their services.

The respondents listed in this suit include Tom Nash, Kevin Paffrath, Jaspreet Singh, Graham Stephan, Ben Armstrong, Andrei Jikh, Brian Jung, Erika Kullberg and Jeremy Lefebvre. All these are individuals who have YouTube accounts that they used to promote FTX; the suit also mentions the founder of talent management firm Creators Agency LLC, which was in charge of overseeing the promotion of the now-defunct crypto exchange FTX.

In the lawsuit, the plaintiffs describe those they are suing as individuals (influencers) who positioned themselves as actual consumers who were sharing their valuable, authentic experiences of the product with those who follow them on YouTube.

The seven people named as plaintiffs come from various countries around the world, and the common factor bringing them together is their purchase of what they say was an unregistered security that was, for personal financial motives, promoted by the persons accused in the lawsuit. The plaintiffs say the actions of the influencers were also geared at benefiting FTX as a company.

The lawsuit goes further to enumerate national as well as global categories of plaintiffs who suffered losses in some way due to the actions of the defendants. As such, damages in excess of a billion dollars are being demanded from the defendants.

It is interesting to note that the lawsuit points out that back in 2017, the U.S. Securities & Exchanges Commission (SEC) issued a warning to the effect that any individual found to be promoting what is later proved to have been an unregistered security risked being prosecuted for their failure to disclose that they were being paid or compensated to promote the said security. The suit adds that recent developments have shown that the SEC regards the products that FTX was offering as unregistered securities as evidenced in the cases they are prosecuting or investigating against different actors in the crypto space.

It now remains to be seen how this consolidated class-action matter is resolved by the court and how that decision will impact the crypto world and its different actors such as HIVE Blockchain Technologies Ltd. (NASDAQ: HIVE) (TSX.V: HIVE).

HIVE Blockchain Technologies Ltd. (HIVE), closed Friday's trading session at $3.12, off by 2.8037%, on 688,846 volume. The average volume for the last 3 months is 148,515 and the stock's 52-week low/high is $1.36/$11.70.

Fisker Inc. (FSR)

Schaeffer's, InvestorPlace, StocksEarning, QualityStocks, MarketBeat, MarketClub Analysis, Kiplinger Today, The Street, The Online Investor, Daily Trade Alert, Early Bird, Trades Of The Day, StockEarnings, Investopedia, Money Wealth Matters, TradersPro, StreetInsider, Cabot Wealth, TipRanks, wyatt research newsletter, CNBC Breaking News and InvestorsUnderground reported earlier on Fisker Inc. (FSR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The cost of lithium, a key element in all EV batteries, has significantly decreased, making electric vehicles relatively affordable. This is great news for consumers. However, experts differ on the duration for how long low costs will persist. Several observers were surprised by the sudden changes because they had assumed that the prices would remain high or even increase, impeding the switch to greener transport methods, a crucial step in the fight against global warming.

The decline in material costs has made it simpler for automakers to lower the cost of electric cars. For example, this year saw Tesla reduce the prices of two vehicles in its lineup — the Model X sport utility and Model S sedan — throughout the month of March by significant fractions. This came after price cuts in January on two other more affordable vehicles, the 3 and Y models.

Cost is the main obstacle for electric cars, according to Kang Sun; hence, the decline in lithium prices is likely to encourage electric vehicle sales. Sun believes costs might decrease far more since the metal’s demand hasn’t increased as quickly as industry experts anticipated.

There are differing views on what led to the latest decline in lithium pricing and also on its future prices, just as there are for every other product. While a few analysts argue that the decline in lithium prices was brought on by the slowdown in global economic development alongside the end of subsidies for EV purchases in China and Europe, others are of the view that the decline was evidence that the lithium crisis was being resolved more quickly than several analysts had anticipated, thanks to new mining and processing facilities.

Lithium prices, despite their steep decline, are still high, making the extraction and refining of this metal an incredibly profitable venture that has drawn in banks and investors to fund or loan mine and refining enterprises. More funding should come from the federal government.

Lithium is widely available across the globe. Yet up until the past one or two years when EV sales started to soar, it was not seen as particularly valuable. The auto sector hurriedly opened additional mines to be able to meet the rising demand, and refineries expanded their ore-processing capacity.

According to Bold Baatar, the pricing is not being driven by mining but rather by the accessibility of processing plants. There is currently no technology that could make mass production of automotive batteries without lithium. Because of this, a few analysts believe that the price of lithium will drop further as in 2020 when prices dropped below $10/kg.

As electric vehicles become more affordable, we can expect models from various manufacturers such as Fisker Inc. (NYSE: FSR) to become commonplace on roads around the world as ICE vehicles fall out of favor.

Fisker Inc. (FSR), closed Friday's trading session at $5.73, even for the day, on 4,756,546 volume. The average volume for the last 3 months is 596,094 and the stock's 52-week low/high is $5.54/$14.74.

The QualityStocks Company Corner

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT) .

HeartBeam (NASDAQ: BEAT) is developing the first and only 3D-vector ECG platform for heartattack detection anytime, anywhere. “By applying a suite ofproprietary algorithms to simplify vector electrocardiography(‘VECG’), the HeartBeam platform will enable patients and theirclinicians to determine quickly and easily if symptoms are due to aheart attack so care can be expedited if required. HeartBeam hastwo patented products in development. HeartBeam AIMI(TM) issoftware for acute care settings that provides a 3D comparison ofbaseline and symptomatic 12-lead ECG to identify a heart attackmore accurately. HeartBeam AIMIGo(TM) is the first and onlycredit-card-sized, 12-lead output ECG device coupled with asmartphone app and cloud-based diagnostic software system tofacilitate remote heart-attack detection,” a recent articleexplains. “At HeartBeam, we are addressing the need to determine ifsomeone who is experiencing signs of a heart attack at home, workor any place outside of a medical setting is actually experiencingone,” HeartBeam CEO and Founder Branislav Vajdic, PhD, is quoted assaying. “It’s a huge issue. On average, most people wait over threehours before seeking care… That time means that the mortality rategoes up by some 40%.”

To view the full article, visit https://ibn.fm/7ZsIp

HeartBeam Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector 12-lead electrocardiogram (ECG) platform for heart attack detection anytime, anywhere. The company’s proprietary ECG telehealth technology aims to redefine the way high risk cardiovascular patients are diagnosed in ambulatory and acute care settings. HeartBeam’s initial focus is on providing diagnostic data to help physicians with care management of patients with cardiovascular disease.

In August 2022, HeartBeam announced that it submitted its HeartBeam AIMI™ software for approval from the U.S. Food and Drug Administration (FDA). HeartBeam AIMI is a platform technology to improve the speed and accuracy of heart attack detection in acute care settings. The company expects FDA approval by the end of 2022, and a full commercial roll-out of HeartBeam AIMI is targeted for Q1 2023.

HeartBeam sees submission of its first product based on its platform technology as an important milestone toward commercialization, which underscores the company’s continued progress toward making the HeartBeam AIMI platform widely available to help emergency department physicians quickly and accurately identify a heart attack.

While the FDA conducts its regulatory review, HeartBeam will focus on executing key components of its commercialization plan and subscription revenue model. It will also continue to engage in discussions with strategic institutions, including academic centers, regional healthcare systems and regional community hospital systems that can utilize HeartBeam products.

The company is based in Santa Clara, California.

Products

HeartBeam’s development portfolio includes two products:

  • HeartBeam AIMI is software that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack in acute care settings and, as noted above, has been submitted for FDA approval; and
  • HeartBeam AIMIGo™, the first and only credit card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system for remote heart attack detection.

HeartBeam is developing AIMIGo, a medical-grade detection and monitoring technology for use in remote heart attack detection, thereby allowing physicians to diagnose a patient’s heart attack as it occurs, even if the patient is not at a medical facility. The company’s system, once approved by the FDA, can be used by patients at home or almost anywhere and anytime to help their physicians assess whether chest pain is the result of a heart attack or another cause. While approximately 82% of chest pain ED visits are unnecessary, patients delay approximately 3 to 4 hours after symptoms begin, increasing mortality rates by 40%. The company’s goal is to shorten the time to treatment outside of the medical facility to improve patients’ well-being.

HeartBeam’s AIMIGo is a powerful, portable and easy-to-use prescription-based product. It comprises a smartphone app, a credit card-sized ECG device placed on a patient’s chest, the HeartBeam cloud platform, and a digital portal for the physician to view ECG results and direct patient action. For the first time outside of a medical setting, HeartBeam AIMIGo enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if needed.

Pending FDA clearance, AIMIGo is initially intended to be available by prescription, and is reimbursable under existing remote patient monitoring codes (RPM codes). This provides a new revenue stream to physicians who before did not have a way to monitor these high-risk patients. The RPM codes provide a monthly reoccurring revenue stream to the company, as well. On average, at current reimbursement rates, the practice will receive $1,300+ per year per patient they monitor, and the company will receive $600 per year per patient from this RPM reimbursement.

Market Overview

Adoption rates of telehealth services increased dramatically in recent years, with the COVID-19 pandemic serving as a major driver of growth. Among the areas seeing the greatest expansion are cardiology, radiology, behavioral health and online consultation.

Encouraging this growth, governments are actively developing new policies and reimbursement guidelines to promote the use of digital health platforms. The U.S. Centers for Medicare & Medicaid Services (CMS), for example, has recently expanded reimbursement for telehealth services. U.S. market growth is also being driven by the rising prevalence of chronic conditions and the growing geriatric population.

Remote heart attack detection is a previously unsolved problem with a massive and underserved market that is several times larger than the $2 billion total addressable market (TAM) in the U.S. for ECG cardiac arrhythmia monitoring.

Approximately 8 million Americans have suffered at least one heart attack, and a total of 18 million have been diagnosed with coronary artery disease (CAD). Based on these figures, HeartBeam projects a total addressable U.S. market TAM valued at $10 billion annually for its AIMIGo solution for remote heart attack monitoring of CAD.

Management Team

Branislav Vajdic, Ph.D., Chief Executive Officer and Founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam’s technology to fit his vision for the company. Prior to HeartBeam, from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space. From 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management position. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices, as well as chip design. Dr. Vajdic holds a Ph.D. in Electrical Engineering from the University of Minnesota.

Jon Hunt, Ph.D., has over 35 years’ experience in the medical/medical device industry with extensive domestic and international experience in general management, clinical/regulatory, sales and marketing. He also has diverse experience in Fortune 500 companies, as well as start-up environments. Dr. Hunt was the Vice President of Clinical Science and Technology, Medical Device Innovation Consortium, from July 2019 to July 2021, and Vice President of Clinical and Regulatory Affairs, Cryterion Medical from January 2018 to June 2019 (acquired by Boston Scientific Corporation in July 2018 for $202M). Dr. Hunt was the Founding President and CEO of Bardy Diagnostics, Inc. from October 2013 to November 2017 (acquired by Hill-Rom Holdings, Inc.). Prior to joining Bardy Diagnostics, Dr. Hunt spent the previous 11 years as the Vice President of Clinical & Regulatory Affairs with Cameron Health, Inc. (acquired by Boston Scientific Corporation). Dr. Hunt spent the previous 10 years with Cardiac Pacemakers, Inc., St. Jude Medical and Cardiac Pathways Corporation. Dr. Hunt began his career with Cardiac Pacemakers, Inc. (now Boston Scientific Corporation) as the Director of Clinical Programs. He subsequently held positions at St. Jude Medical in Clinical Affairs and as the Business Unit Director for the Cardiac Rhythm Management division for Europe, the Middle East and Africa. At Cardiac Pathways Corporation, Dr. Hunt held various executive positions as Vice President of International Sales and Marketing and Vice President of Worldwide Sales and Marketing (acquired by Boston Scientific Corporation). Dr. Hunt received his Ph.D. in Motor Control from The Pennsylvania State University, his Master’s from California State University, Long Beach and his undergraduate degree from Keele University in the United Kingdom.

Rick Brounstein, HeartBeam’s Chief Financial Officer, combines over 30 years of experience in health technology senior management. Since 2017, Mr. Brounstein has been and is currently a partner of Hardesty, LLC, a financial services firm, and Mr. Brounstein is currently a managing director of CTRLCFO, LLC, a firm Mr. Brounstein founded in 2016 to support funded start-ups in life science and technology. From 2008 to 2011, Mr. Brounstein was Chief Financial Officer of NewCardio, Inc., a microcap public company in the cardiology space, and, over his career, he has been with nine other companies in life science or technology, holding positions including Chief Financial Officer, Chief Operating Officer, Treasurer and Accounting Manager. From June 2001 through November 2007, Mr. Brounstein held several positions at Calypte Biomedical Corporation, a publicly traded medical device company, including Chief Financial Officer and Executive Vice President. In January 2007, Mr. Brounstein was appointed as the National Member Representative for the 2007 COSO Monitoring Project, which published new guidelines for monitoring internal financial controls in February 2009; Mr. Brounstein subsequently was a member of the FEI task force that issued the updated COSO Internal Control Framework in 2013. In March 2005, Mr. Brounstein was appointed to the SEC Advisory Committee on Smaller Public Companies. Mr. Brounstein earned his Certified Public Accountant (CPA) certification while working at Arthur Andersen LLP, formerly a public accounting firm. Mr. Brounstein holds a B.A. in accounting and an M.B.A. in finance, both from Michigan State University.

Ken Persen, HeartBeam’s Chief Technology Officer, combines over 28 years of experience in the medical device and digital health industries in engineering and senior management positions. Mr. Persen has been involved in several companies in Cardiac Rhythm Management, holding positions including Chief Executive Officer, Chief Technology Officer, Executive Vice President and Director of Engineering. Since 2016 and prior to joining HeartBeam, Mr. Persen was the Chief Technology Officer at LIVMOR, Inc., a digital health company. In addition, from 2016 through November 2021, he was also Chief Executive Officer of LIVMOR. Prior roles included Director of Engineering at Cameron Health (acquired by Boston Scientific), a late-stage medical device start up, and engineering and management positions at Guidant Corp. (acquired by Boston Scientific), a large medical device manufacturer. He has an undergraduate degree from University of Minnesota, Duluth, with a BA in Computer Science.

HeartBeam Inc. (NASDAQ: BEAT), closed Friday's trading session at $2.515, up 6.1181%, on 23,805 volume. The average volume for the last 3 months is 9,597 and the stock's 52-week low/high is $1.12/$6.74.

Recent News

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

Silo Pharma (NASDAQ: SILO) is a developmental-stage biopharmaceutical company focused onmerging traditional therapeutics with psychedelic research. “SiloPharma has distinguished itself amongst peers for itsground-breaking research into conditions such as post-traumaticstress disorder (‘PTSD’), fibromyalgia, Alzheimer’s disease, andother rare neurological disorders. The company has recently enteredinto a number of studies designed to develop innovative solutionsfor previously underserved conditions,” a recent article reads.This comes as a recent study found that psychedelic drugs couldshow promise as a therapeutic alternative in treatingdrug-resistant depression. “What the study found was thatpsychedelics were increasingly able to access receptors insidecells which standard antidepressants could not normally affect,thereby increasing the level of serotonin secreted within the brain– largely because of their ability to pass through cells’ fattyouter membranes to reach the additional receptors within… Withpsilocybin and psychedelic-based therapeutic treatment increasinglygaining favor amongst the medical community and with a risingprevalence of depression and mental disorders within modernsociety, forecasts have now projected the psychedelic drugs marketto swell to a value of $6.8 billion by 2027, representing a CAGR of16.3% within the forecast period of 2020 to 2027. As a frontrunnerin the sector and with a number of research and drug developmentalinitiatives underway, Silo Pharma finds itself well positioned tocapitalize on the growth of the market going forward.”

To view the full article, visit https://ibn.fm/SIFLt

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.

Research

Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Friday's trading session at $2.06, up 0.980392%, on 14,164 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $6.74/$.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS recently enrolled the first patient in Spain in its ongoingglobal trial evaluating its lead drug candidate, Berubicin, for thetreatment of recurrent glioblastoma multiforme (“GBM”)

This milestone is the culmination of years of meticulous planningand execution

The enrollment of this first patient follows the opening of 37clinical trial sites of the 59 sites selected across the UnitedStates, Italy, France, Spain and Switzerland

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in thedevelopment of novel treatments with a focus on brain cancer,glioblastoma and neuro-oncology, just enrolled its first patient inSpain, marking a key milestone in its GBM clinical study.Considered a potentially pivotal global trial for the company, thestudy seeks to evaluate Berubicin, the company’s lead drugcandidate, for the treatment of recurrent glioblastoma multiforme(“GBM”), an aggressive and incurable form of brain cancer. In mostcases, the early discovery of cancer is directly tied to a patient’s chances of surviving thecondition. Completely curing cancer may not be an option, butclinicians have several tools that allow them to kill off themajority of cancer cells and prevent them from spreading to healthytissue. Surgery is usually considered when a tumor is present in only one part of the body and can be surgically removed in allits entirety. This approach to cancer treatment tends to be seen as“curative” because it seeks to completely remove cancer cells fromthe body. In many cases, surgery can allow cancer patients to livea long time after their diagnosis without taking a significant hitto their quality of life. Researchers from University CollegeLondon and Great Ormond Street Hospital (GOSH) have come up with atechnique that can make cancer-removal surgery more effective byincreasing the treatment’s precision and accuracy. They came upwith a technique that allowed them to use infrared light toidentify real-time and highly detailed images of the body’sinterior to differentiate between healthy tissue and canceroustumors.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Friday's trading session at $1.14, up 8.5714%, on 26,604 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.9903/$13.425.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

A new analysis shows that residents in the state of Wisconsinbought $121.2 millions worth of cannabis from licensed retailers in Illinois last year. This contributedroughly $36 million in taxes to the neighboring state. The data wasrequested by Melissa Agard, the Senate Majority Leader, who askedthe Legislative Fiscal Bureau to look into how much was going intoIllinois through out-of-state marijuana purchases. Agard has inpast sessions sponsored legalization measures. The nonpartisanbureau released its results last week after examining data obtainedfrom the Department of Financial & Professional Regulation inIllinois, which breaks down monthly out-of-state and in-statemarijuana sales. These estimates were premised on an assumptionthat all the out-of-state cannabis purchases within countiesbordering Wisconsin were by the state’s residents. Besides taxbenefits, states stand to create significant job opportunities whenmarijuana is legalized because companies serving that space, suchas Advanced Container Technologies Inc. (OTC: ACTX), could grow and need additional manpower as they pursue marketopportunities that results from such legislation.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Friday's trading session at $0.2935, up 17.4%, on 657 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.1261/$1.25.

Recent News

Coyuchi Inc.

The QualityStocks Daily Newsletter would like to spotlight Coyuchi Inc.

  • California-based sustainable bed and bath comfort brand CoyuchiInc. has established its brand not only on the luxury of itsproducts, but the organic sourcing of the textiles it uses
  • Consumers increasingly are scrutinizing the sourcing of theirhome decor products in search of evidence they are friendly toearth’s climate and responsibly produced
  • Coyuchi’s management team brings experience in corporatefunction and an enthusiasm for sustainability in the company’ssourcing and partnerships
  • The company launched a Reg A+ investment offering last yearthat led to a capital raise topping $1 million

One significant driver in choosing fabrics for home decor thesedays is determining where they are sourced. “Homeowners, more thanever, are paying close attention to what their home fabrics aremade of and where they have come from,” a recent report drawing ondecorator’s insights states (https://ibn.fm/eKQUm). Luxury bed, bath, and apparel product company Coyuchi devotes its corporate purpose to being “responsible beyond thethread” — using cotton and linen certified to the Global OrganicTextile Standard (“GOTS”) respected as the most rigorous around theworld, and extending beyond that to product use and recyclingconsiderations.

Coyuchi is the gold standard in sustainable luxury home goods. The company offers sustainably produced luxury organic bedding, sheets, towels, apparel, and other home goods for the environmentally conscious home. With a timeless, coastal-inspired aesthetic, Coyuchi uses only 100% organic cotton materials to manufacture all of its textiles.

The Company was built upon four foundational pillars: protect the planet, innovate circular design, live sustainably, and enrich the community. These guiding principles have proven an effective market strategy. In 2021, Coyuchi earned $33.3 million in net sales, amounting to 26% YoY growth (the industry average is only 5%). It also experienced 2x customer growth to 200,000 active customers, averaging a 35% customer repeat purchase rate.

With a seasoned leadership team, a robust e-commerce shopping experience, and a healthy customer base that drives the fast-growing organic luxury market, Coyuchi is prepared to propel a new phase of growth as the rest of the world finally awakens to sustainability at scale.

A Lucrative Market Ripe for the Taking

The global market for organic bedding, which was estimated at $814.3 million in 2020, is projected to reach $1.1 billion by 2027, growing at a CAGR of 4.9% over that period, according to Research and Markets. More specifically, the domestic organic bedding market is estimated at $240.1 million in 2020, according to Statista. Overall, the U.S. market for home textiles is currently valued at $25 billion annually, and, with a forecast annual growth rate of 5%, it is expected to reach $30 billion by the end of 2025.

Grand View Research reported in 2020 that shifting consumer preference toward high-end lifestyle products is a key factor driving the growth of the organic bedding market. Seventy-four percent of consumers are willing to pay more for sustainable products – a consumer preference that has steadily increased over the last few decades. Millennials especially favor ethical consumption over price when purchasing goods and services, with 83% of millennials reporting that they want the brands they purchase from to align with their beliefs and values (https://ibn.fm/PANNV). With a majority millennial customer base, Coyuchi is poised to capitalize on this trend.

Industry Defining Sustainability Practices

For 30 years, Coyuchi has explored organic farming and sustainable textiles and guarantees the highest environmental and ethical standards through a number of certifications such as The Global Organic Textile Standard (GOTS), Fair Trade Certified, and MADE SAFE®.

Coyuchi continues to push the organic textile market forward through its circularity initiatives and by supporting cross-industry sustainability advocates. Coyuchi’s mission to bring beauty and comfort to every home without sacrificing the health of our planet has resulted in a number of important sustainability checks and balances.

  • A Circular Business Model: Coyuchi has cultivated a holistic 360-degree approach that contributes to the fight against climate change with its take back and recycling program, 2nd Home™. In 2017, it became the first luxury home brand to implement such an initiative, and, since then, the company has eliminated 68,758 lbs. of toxic chemicals from homes and renewed 6,000 lbs. of textiles.
  • The Coyuchi Climate Council: In early 2022, Coyuchi introduced a cross-disciplinary council with a goal of Net Zero Emissions by 2025 and Net Positive Emissions by 2030. The Coyuchi Climate Council brings together influential minds across fashion, regenerative farming, and sustainability who have the knowledge and experience necessary to achieve climate change.
  • C4: The California Cotton & Climate Coalition: Most recently, Coyuchi announced it is a founding member of C4, which includes innovative, sustainable fashion, apparel, and personal care brands like MATE the Label, Outerknown, Reformation, and Trace. Working together pre-competitively, C4 creates a structure for investing in regionally grown, Climate Beneficial™ cotton and directly supports the livelihoods of the farmers that grew it. Coyuchi is the only home industry brand currently involved in the project.

Omnichannel Business Model

Coyuchi differentiates itself through an omnichannel and circular business model, both of which have proven a clear draw for customers. It was an early adopter of an e-commerce sales and marketing approach (over 80% of its sales are directly through coyuchi.com), creating a distinct advantage over incumbents and start-up newcomers in the luxury space. This has resulted in a high lifetime value customer, luxury retail partners such as Nordstrom, and a flagship store in Marin County.

Coyuchi’s Organic Textile Products

Coyuchi’s product assortment consists of consciously designed bedding, bath, apparel, and lifestyle products spread across about 1,400 SKUs. The company believes that its product assortment, produced from 100% organic cotton with Global Organic Textile Standard (GOTS) certification, provides it with a significant competitive advantage. GOTS is the world’s leading textile processing standard for organic fibers, ensuring the organic status of textiles after harvesting raw materials through environmentally and socially responsible manufacturing all the way to labeling, a major environmental and social benefit over conventional cotton product production.

Coyuchi’s focused product assortment consists of four core categories:

  • Bedding – A full suite of sustainable, organic, and high-quality sheets, duvet covers, blankets, and throws.
  • Bath – A luxurious line of towels, bath rugs, and mats.
  • Apparel – Premium apparel for men and women, including robes, sweaters, pants, and pajamas.
  • Lifestyle – The lifestyle category offers 135 SKUs, from organic napkins to crossbody totes.

Management Team

Eileen Mockus is President and CEO at Coyuchi. She has more than 25 years of experience in retail, having held positions in textile development at Patagonia, Pottery Barn Teen, and The North Face. She earned a bachelor’s degree in textiles and clothing from UC Davis and an MSBA from San Francisco State University.
Sejal Solanki is Chief Marketing Officer at Coyuchi. She previously served as the company’s Vice President of E-Commerce. Before joining Coyuchi, she worked at teen clothing giant Charlotte Russe. She oversees the company’s digital marketing, site experience, brand marketing, and e-commerce strategy.

Marcus Chung is Coyuchi’s COO, overseeing supply chain, sourcing strategy, sustainability, and IT. He previously held positions at notable direct-to-consumer brands Third Love and Stitch Fix, as well as national retailer The Children’s Place. He holds a bachelor’s degree from Wesleyan University and an MBA from UC Berkeley’s Haas School of Business.

Margot Lyons is Director of Sustainability and Sourcing at Coyuchi, where she works with strategic partners to ensure all the company’s product sustainability standards are met. She received a master’s degree in textiles and clothing from UC Davis.

Use of Proceeds

This round of funding will be used to increase Coyuchi’s enterprise value through expanded marketing, product category expansion, continued physical presence, and B2B strategic partnerships with wholesalers, and online marketplaces.

Recent News

chart

Progressive Care Inc. (OTCQB: RXMD)

The QualityStocks Daily Newsletter would like to spotlight Progressive Care Inc. (OTCQB: RXMD).

Progressive Care reported a 4% year-over-year revenue increase toapproximately $10.1 million for the quarter ended September 30,2022

The company’s prescription revenue increased 16% year-over-year toalmost $9.4 million during that same period

In 2022, Progressive Care received nearly $6 million from astrategic investment transaction with NextPlat Corporation

The company launched its ClearMetrX platform for 340B third-partyadministration in 2022

Progressive Care will partner with MedAvail in2023 to provideprescription dispensing kiosks

Progressive Care Inc. (OTCQB: RXMD) is a health services organization based in Florida that offers personalized healthcare services and technology that supports the managed healthcare industry. Through its subsidiaries, Progressive Care provides Third-Party Administration (TPA), data management and analytics, COVID-19 diagnostics and vaccinations, 340B contracted pharmacy services, compounded medications, tele-pharmacy services, dispensing of anti-retroviral medications, medication therapy management (MTM), long-term care facility-targeted prescription medications, and health practice risk management.

The company collaborates with various healthcare organizations such as managed care organizations (MCOs), management services organizations (MSOs), accountable care organizations (ACOs), primary care providers, Medicare Advantage plans, Medicaid, commercial payors, pharmaceutical manufacturers, and distributors to enhance patient and provider engagement while improving the lives of patients with chronic diseases. Progressive Care offers a wide range of innovative solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs.

Progressive Care currently operates four pharmacies in Florida, which generate the majority of its revenue. Pharmacy revenue is derived from dispensing medications, third-party administrative services to 340B-covered entities, and MTM services. The company also provides customized management, patient health risk reviews, and free same- and next-day delivery. Its focus is on complex chronic diseases that require multiyear or lifelong therapy, driving recurring revenue and sustainable growth. Progressive Care’s pharmacy revenue growth stems from its expanding breadth of services, new drugs coming to market, new indications for existing drugs, volume growth with current clients, and addition of new customers resulting from its emphasis on higher patient engagement, free delivery to the patient, and clinical expertise.

With licenses in 14 states, Progressive Care is poised for national expansion. The company anticipates revenue growth by signing new contract pharmacy service and data management contracts with 340B-covered entities, expanding data management and analytics services to healthcare organizations, and potential acquisitions.

Subsidiaries

Progressive Care’s wholly-owned subsidiaries provide services to client organizations and patients.

PharmcoRx Pharmacy

PharmcoRx, a full-service pharmacy, provides a complete healthcare ecosystem with services such as medication therapy management, rapid COVID-19 testing and vaccines, contactless medication delivery, Smart-Pack Unit Dosing packaging, custom compound medications, specialty medications, hospital transition pharmacy services, medication adherence monitoring, medication adherence risk management, and drug cost containment. PharmcoRx Pharmacy is a contracted pharmacy services provider for 340B-covered entities under the 340B Drug Discount Pricing Program.

ClearMetrX

ClearMetrX, a wholly-owned data management company, offers services that support healthcare organizations across the country. In September 2022, ClearMetrX launched the 340MetrX Platform, a software product developed by ClearMetrX that provides 340B-covered entities with data insights to effectively operate and maximize the benefits of the 340B program. 340MetrX supplies data access and delivers actionable insights that providers and support organizations can use to improve their practices and patient care. Its TPA services include management of wholesale accounts and contract pharmacies, patient eligibility with regard to the 340B drug program, development and review of 340B policies and procedures, and management of receivables.

Market Opportunity

According to an industry report by global consulting firm Berkeley Research Group, gross sales across the 340B drug program were valued at $116 billion in 2021 and are projected to grow to $280 billion by 2026, achieving a CAGR of more than 19% over the period.

The 340B drug pricing program allows eligible healthcare clinics and hospitals (the covered entities) to purchase outpatient drugs at a 20-50 percent discount to treat low-income, uninsured, or underinsured populations. The program’s forecast growth is expected to benefit Progressive care’s business of providing 340B program services to covered entities through the nationwide expansion of ClearMetrX, its third-party administration and data-management business.

Management Team

Charles M. Fernandez is CEO and Chairman of the Board of Directors of Progressive Care. Mr. Fernandez is also the Executive Chairman and CEO of NextPlat Corp. (NASDAQ: NXPL) and has over 30 years of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. In 2008, he joined Fairholme Capital Management. As president, he co-managed all three Fairholme funds and was commended for bringing in a $2 billion gain for shareholders. Throughout his impressive career in media, pharmaceuticals, healthcare, finance and technology, Mr. Fernandez has participated in more than 100 significant mergers, acquisitions and product development projects. He was the founder, chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK) which was successfully sold to Smartrac, a leading developer, manufacturer and supplier of RFID and Internet of Things (“IoT”) solutions and a unit of Avery Dennison Corporation (NYSE: AVY).

Other top management team members include Chief Operating Officer Birute Norkute, Chief Financial Officer Cecile Munnik, and Pamela Roberts, who serves as the company’s Pharmacist in Charge.

FingerMotion Inc. (RXMD), closed Friday's trading session at $3.7, off by 2.6316%, on 6,575 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.00/$10.40.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

DehydraTECH(TM) is suitable for use with a wide range of productformats, including pharmaceuticals, nutraceuticals, andover-the-counter capsules, pills, tablets, topicals, oralsuspensions and more

The patented technology increases the speed of onset,bioavailability, brain absorption, and reduces drug administrationcosts

Lexaria currently has multiple R&D programs – yieldingsuccessful results and further opportunities for additional studymodels

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator developing and commercializing its patentedDehydraTECH(TM) drug delivery technology. Lexaria is continuingand/or initiating discussions with several larger companies inEurope and North America regarding the licensed use of itstechnology for both consumer and pharmaceutical sectors. “Thematerialization of such partnerships hinges on a number ofmust-haves. Firstly, there must be a tangible product that drawslarger companies. Secondly, The decision of whether or not toinvest, and the scale of any investment, is based on how well thetechnologies that form the core of a company have been protected.This is where patents come in. Moreover, the further a company cantake its own research, the better the deal that will be offered interms of upfront payments, milestone payments, and royalties,”reads a recent article that contains excerpts froma LabioTech writeup. “Lexaria ticks all these boxes. Its uniquetechnology – DehydraTECH – is not only tangible but has also beenshown to enhance the performance of several categories offat-soluble active molecules and drugs across various oral andtopical product formats. The technology is also protected by arobust portfolio of 28 patents granted worldwide as of February2023… Lastly, and perhaps most importantly, Lexaria hassubstantially invested in research and development (‘R&D’), anaspect of its operations that is 100% within its control. Accordingto CEO Chris Bunka, the company has designed its applied R&D toboost its commercial prospects, and this ‘is paying off in spades,’as it has, among others, ‘yielded almost entirely positiveresults.’”

To view the full article, visit https://cnw.fm/dikY2

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Friday's trading session at $2.5, off by 2.3438%, on 9,241 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.80/$4.83.

Recent News

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturingand commercializing innovative immunotherapeutic products primarilyfor the treatment of infectious and autoimmune diseases. “BiondVaxis seeing convincingly positive outcomes for preventing andarresting disease in COVID patients during an ongoing preclinicalin vivo study, even as continually evolving variants are shuttingdown emergency-use authorization (‘EUA’)-approved avenues oftreatment that may no longer be effective… However, BiondVax’sdevelopment of a nanosized antibody (‘NanoAb’), that to date hasshown neutralization of all relevant Omicron subvariants, isgenerating excitement as a potential superior prophylactic approachto COVID prevention… At-risk groups, such as the elderly and peoplewith comorbidities, may proactively be able to protect themselvesthrough the company’s conveniently self-administered inhaled NanoAbtherapy,” a recent article reads. “NanoAb therapeutics have thepotential to quickly and effectively address new variants,”BiondVax CEO Amir Reichman is quoted as saying.

To view the full article, visit https://ibn.fm/U4HN0

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Friday's trading session at $2.17, off by 2.2523%, on 8,021 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.0333/$22.90.

Recent News

Freight Technologies Inc. (NASDAQ: FRGT)

The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).

Freight Technologies (NASDAQ: FRGT), a technology company offering its custom-developed Fr8App, hasannounced a reverse share split. The move is designed to increasethe market price per share of the company’s ordinary share, therebyresulting in Freight Technologies regaining compliance withNASDAQ’s minimum bid price requirement and maintaining its NASDAQCapital Market listing. FRGT board of directors approved the 10:1reverse split on March 3, 2023; the split will be effective on oraround March 24, 2023. According to the announcement, the company’sordinary shares will continue to trade on NASDAQ under the symbolFRGT but will trade under a new CUSIP number: G514113113. Fr8App isan industry-leading freight-matching platform powered by AI andmachine-learning that offers a real-time portal for B2Bcross-border and domestic shipping within the USMCA region.“Freight Technologies is on a mission to first disrupt thenrevolutionize cross-border shipping and domestic shipping withinthe United States-Mexico-Canada region,” said Freight TechnologiesCEO Javier Selgas in the press release. “Maintaining NASDAQ listingis important for both the company and the shareholders. Weanticipate these actions will maintain our NASDAQ listing asevermore shippers and carriers continue to turn to FreightTechnologies for our unique streamlined solutions in cross bordershipping and logistics.”

To view the full press release, visit https://ibn.fm/xn8Ey

Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

  • Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
  • Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
  • Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
  • Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
  • Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
  • Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Commitment to the Environment

Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.

Fr8University

Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.

Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.

Market Outlook

Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.

Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.

Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.

Management Team

Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.

Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).

Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.

Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.

Freight Technologies Inc. (NASDAQ: FRGT), closed Friday's trading session at $1.69, up 894.1177%, on 2,173,781 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.49/$31.90.

Recent News

Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF)

The QualityStocks Daily Newsletter would like to spotlight Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF).

The European Union (EU) has added copper and nickel to its list ofcritical minerals at a time when both metals are facing significant shortages. Critical or strategic minerals are either nonmetallic or metallicelements that play a significant role in the function of moderntechnology, national security or economies, and that face aninherent risk of supply chain disruption. Copper is crucial in the development of renewable energy technologies and electric cars while nickel is a major raw ingredient inelectric vehicle batteries. As the world strives to move away fromdirty energy sources such as oil and coal to renewable sources,including solar and wind power, metals such as nickel and copperwill be integral. However, the world is currently plagued with acopper shortage that is expected to last until 2030. The current market dynamics paint a bullish picture for miningcompanies such as Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF) that are looking to commence commercial production of nickel attheir development sites.

Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF) is advancing the next generation of nickel-cobalt sulfide projects to deliver the metals needed to power the electric vehicle (EV) revolution and feed the high growth stainless steel market. The company is one of only a few new sources of potential supply outside Indonesia and China.

Canada Nickel possesses industry leading nickel expertise and is focused on low risk, well established mining jurisdictions. The company has launched wholly owned subsidiary NetZero Metals Inc. to develop zero-carbon production of nickel, cobalt and iron and has applied in multiple jurisdictions to trademark the terms NetZero Nickel, NetZero Cobalt and NetZero Iron. Canada Nickel is also pursuing development of processes to allow net zero carbon production of these elements.

Canada Nickel is currently anchored by its 100% owned flagship Crawford Nickel-Cobalt Sulfide Project with large-scale potential located in the heart of Ontario’s prolific Timmins-Cochrane mining camp, adjacent to major infrastructure.

The company believes the EV industry and many other consumer sectors have an urgent need for zero-carbon metal this decade, not in 20-25 years as contemplated by some resource companies. Canada Nickel also believes that nickel supplies from Indonesia and other Pacific island nations, typically controlled by Chinese-owned companies, are not the answer for batteries needed by GM, Ford and the European automakers working to develop and manufacture EV models.

The company is headquartered in Toronto.

Crawford Nickel-Cobalt Sulfide Project

The Crawford Nickel-Cobalt Sulfide Project is the largest sulfide discovery since the early 1970s and contains the fifth-largest nickel sulfide resource in the world, based on Measured & Indicated resources, according to the latest update. The Crawford project is expected to be one of the largest base metal mines in Canada based on results of a Preliminary Economic Assessment. Early projections by Canada Nickel estimate that the project has the potential to produce 50,000 tons of nickel per year. The company is now in the final stages of completing the project’s feasibility study.

The project is projected to produce 2.8 tons of CO2 per ton of nickel equivalent production, which is 89% lower than the industry average of 34 tons of CO2 per ton of nickel equivalent production.

The company is taking significant steps toward developing the Crawford project as a net zero carbon producer. In addition to harnessing the natural ability of the project’s geology to act as a carbon sink through spontaneous reaction of the host rock once exposed to atmospheric conditions called mineral carbonation, Canada Nickel has discovered a new way to enhance carbon capture, termed In Process Tailings (IPT) Carbonation. This act of conditioning the tailings with a concentrated stream of carbon dioxide before deposition has been demonstrated at lab scale to achieve carbon capture at a rate 8-12 times faster than naturally occurring sequestration, achieving more than 60% of the capture that had previously taken six days.

These latest results move the company further toward production of Net Zero Nickel™ and generation of 21 tonnes of CO2 credits per tonne of nickel, which would produce an estimated average of 710,000 tonnes of CO2 credits annually and 18 million total tonnes of CO2 credits over the expected life of mine. IPT Carbonation does not require complex new technologies and major process modifications and could encourage the development of a net zero carbon industrial cluster centered around the Crawford project.

Canada Nickel in January 2023 announced that its latest test work results support the incorporation of carbon capture and storage into the Crawford project. The company believes that utilization of existing process streams should allow IPT to be efficiently engineered and incorporated into the project’s flowsheet, with an integrated feasibility study for the project expected in the second quarter of 2023.

In December 2022, Canada Nickel announced its engagement on Deutsche Bank Securities Inc. (“Deutsche Bank”) and Scotiabank – two of the world’s leading investment banks with a broad base of mining and industrial expertise – as financial advisors for the equity component of the project financing for the Crawford project. In the same release, the company announced the completion of another significant permitting milestone by filing the detailed project description with the Impact Assessment Agency of Canada. Canada Nickel targets receipt of permits by mid-2025, with construction to immediately follow.

Additional Projects

The Reid Nickel Property is located just 16 kilometers southwest of Crawford, or 37 kilometers northwest of Timmins, and contains an ultramafic body with a target geophysical footprint of 3.9 square kilometers. Preliminary assay results from Canada Nickel’s summer/fall drilling program confirm the presence of mineralized dunite, as well as currently undefined higher-grade sections. Partial assay results confirm expected nickel grades. Nickel mineralization in serpentinized dunite was found in all 16 holes drilled to date.

The Sothman Nickel Property is located 70 kilometers south of Timmins. Five drill holes on the eastern half of the target anomaly confirmed the continuation of ultramafic lithologies, primarily peridotite, with moderate to strong serpentinization and variable amounts of mineralization throughout.

The company in December 2022 announced positive drilling results from its ongoing regional exploration campaign at its Reid and Sothman properties. These latest results continue to reinforce the success of Canada Nickel’s geophysical targeting approach and increase the probability of success at the company’s other 20-plus properties within its 42 square kilometers of geophysical targets.

Building on this momentum, Canada Nickel in December 2022 announced its entry into a deal to acquire a 100% interest in the past producing Texmont property situated between the company’s properties south of Timmins. As noted in the news release, the acquisition of the Texmont property provides near-term smaller scale production potential and is highly complementary to the company’s large-scale Crawford and regional nickel sulphide projects.

Market Opportunity

Global demand leaves the market fundamentally short of nickel in the medium- and long-term. Global primary nickel demand will likely reach 3 million tons in 2022, up from 2.4 million tons in 2020, according to the International Nickel Study Group (INSG).

The INSG says primary nickel production is forecast to hit 3.1 million tons in 2022. Indonesia, the world’s largest nickel miner, halted exports of unprocessed nickel ore in January 2020, due to a government-imposed ban. Indonesia has floated the concept of a nickel cartel whose member nations would exert influence over world nickel supply and prices, similar to OPEC’s pricing power over oil.

Benchmark Minerals, a leading EV supply chain research firm, projects that, by 2035, world demand for nickel will double from current levels to 6 million tons annually. That growing demand represents a need for new nickel production equivalent to 70 mines the size of Canada Nickel’s Crawford Project.

Management Team

Mark Selby is Chairman, CEO and Director of Canada Nickel. He was formerly President and CEO of RNC Minerals, where he led a team that successfully raised over $100 million and advanced the Dumont nickel-cobalt project from initial resource to a fully permitted, construction-ready project. He has held senior management roles with Quadra Mining, Inco and Purolator Courier, and was a partner at Mercer Management Consulting. Since 2001, he has been recognized as one of the leading authorities on the nickel market. He graduated from Queen’s University with a Bachelor of Commerce.

Wendy Kaufman is CFO of Canada Nickel. She has 25 years of experience leading publicly listed mining companies in project financing, capital structuring, capital markets, accounting and internal controls, tax, and financial reporting and public disclosure. She was also previously CFO at Khiron Life Sciences Corp. and held CFO and senior finance positions at Pasinex Resources Limited, Primero Mining Corporation and Inmet Mining Corporation. She holds a Bachelor of Business Administration from Wilfrid Laurier University and is a Chartered Professional Accountant.

Steve Balch is VP Exploration at Canada Nickel. He is an Ontario registered geoscientist with 32 years of experience in geophysics, specializing in magnetic and electromagnetic methods. He founded Triumph Instruments and developed the AirTEM system, a multi-coil helicopter-borne EM system that is in use worldwide. He has also been active in borehole geophysics and helped develop new technologies including north-seeking gyros, temperature compensated induction conductivity probes, UAV-based magnetometers and high sensitivity magnetic gradiometers.

Christian Brousseau is VP Capital Projects at Canada Nickel. He is a professional engineer (P.Eng) with over 30 years of experience in engineering, design and construction in the Canadian mining industry, including six years as Project Director for the Dumont Project and three years as the Engineering and Construction Manager for Detour Gold. Prior to Detour, he held various construction management positions at Osisko’s Malartic Project and at Goldcorp’s Éléonore Project. He also spent eight years at Falconbridge supervising and managing various capital projects.

Canada Nickel Company Inc. (OTCQX: CNIKF), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

India Globalization Capital Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital Inc. (NYSE American: IGC).

Mississippi approved the use of medical cannabis last year after a lengthy legislative debate, though localgovernments were given the option to reject the initiative. LincolnCounty was one of the counties that initially declined toparticipate in the program. However, the decision prompted TimothyGibson and Jason McDonald to take the lead in pushing for thelegalization of medical cannabis in the county. The two succeededin getting the issue on the ballot in August last year when countyvoters overturned the decision made by local officials. After thevote, they got to work on starting their own medical cannabis cultivation facility — SADUJA — located in East Lincoln. In December 2022, the facilityreceived a license to cultivate medical cannabis, making it thefirst in Lincoln County. “We have been cultivating hemp since itslegalization in Mississippi,” McDonald said. “We provided hemp toregional stores in the state. People may not have been aware thatcannabis was grown here legally prior to the legalization ofmedical marijuana. It was present and flourishing on the farm.Worries such as those faced by Reeves could soon be partiallyaddressed if organizations such as India Globalization Capital Inc. (NYSE American: IGC) succeed in bringing to market various formulations targeting thedifferent conditions for which patients are enrolling for medicalmarijuana in different jurisdictions around the country.

India Globalization Capital Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule (www.clinicaltrials.gov). As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products (www.Holief.com) such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand (www.SundaySeltzer.com) that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.

IGC-AD1

IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.

TGR-63

The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

India Globalization Capital Inc. (NYSE American: IGC), closed Friday's trading session at $0.339, off by 1.5822%, on 60,165 volume. The average volume for the last 3 months is 1,581 and the stock's 52-week low/high is $0.2785/$1.16.

Recent News

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF).

A recent increase in psychedelic research has found that psychedelics can treat mental health disorders,including anxiety, depression, suicidal thoughts and post-traumaticstress disorder. With 90% of American adults reporting that the country is in the midst of a mental healthcrisis, the research seems to have come at an opportune moment. The growing body of scientific literature has encouraged several lawmakers nationwide to consider measuresto either decriminalize psychedelics or legalize them for medicaluse. Although the number of jurisdictions in America that allowpsychedelic-assisted treatments is still low, it is expected togrow as more legislators pursue psychedelic legalization. To achieve psychedelic reform on a national scale, a political action committee has been formedto rally political candidates who support the medical use ofpsychedelics such as ketamine, MDMA and psilocybin. This committee,the Psychedelic Medicine PAC, will also work to find federalfunding for psychedelic research and education. Those awarenesscampaigns will be the right complement to the data being uncoveredand disseminated by companies such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) that are running psychedelic drug-development programs.

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

  • Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
  • Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
  • Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
  • Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

  • 32 million people in the U.S. have used psychedelics at least once
  • 17% of all American adults between 21 and 64 have used psychedelics at least once
  • $500 billion is spent in the U.S. every year on prescription drugs
  • $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
  • The anxiety disorder and depression treatment market is estimated at $16 billion
  • $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Corp. (DELCF), closed Friday's trading session at $0.005, off by 19.3548%, on 483,490 volume. The average volume for the last 3 months is 68,018 and the stock's 52-week low/high is $0.0031/$0.092105.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.